Study ID: Merck MK7339-002


A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Title: Treatment with Olaparib in HRRm or HRD Positive Cancer Description: The purpose of this study is to test the safety of the study drug (olaparib), see how well the drug works, and see how your body handles the drug. You will take olaparib by mouth twice daily while in the study. To be in the study, you must be at least 18 years of age and have a confirmed solid tumor that is not eligible for curative treatment and has failed standard of care treatment. You cannot have taken the study drug, Olaparib, in the past or have a hypersensitivity to it.
Sioux Falls Region
Principal Investigator:
Steven Powell, MD
Solid Tumors
Phase II
Active - Open to Accrual